Susan E. Moody
0009-0002-7714-1170
Publication & Citation Trends
Most Cited Works
Publications
114 total
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors OA
Cited by 4
Semantic Scholar
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours PDF
Cited by 149
OpenAlex
KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
Cited by 40
Semantic Scholar
Cellular dormancy in minimal residual disease following targeted therapy OA
Cited by 36
Semantic Scholar
Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
Cited by 46
Semantic Scholar
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling PDF
Cited by 160
OpenAlex
Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to ERK inhibition
Cited by 0
Semantic Scholar
Abstract A44: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors
Cited by 1
Semantic Scholar
Research Topics
Protein Tyrosine Phosphatases
(60)
Melanoma and MAPK Pathways
(34)
Synthesis and biological activity
(11)
Lung Cancer Treatments and Mutations
(11)
Protein Kinase Regulation and GTPase Signaling
(10)
Frequent Co-Authors
Affiliations
Broad Institute
Novartis (Switzerland)
American Institutes for Research
Foundation for Biomedical Research
Harvard University